Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $708.73M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.21M
Average 1.39M
SLDB Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Solid Biosciences Inc.NASDAQ: SLDB
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 41.4% from a year ago
Cash & equivalents stood at $297.74M at the end of Q1 FY2026, up 41.4% from a year earlier and up 387.1% from the prior quarter. Over 3 fiscal years it compounded at -27.2% a year.
Context
- Cash & equivalents amounted to 70.4% of total assets at the end of Q1 FY2026, up 9.2 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +41.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 59.9M USD
- Year-over-year change
- -25.3%
- 4-year CAGR
- -15.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 59.9M | -25.3% |
| FY2024 | 2024-12-31 | 80.24M | +8.4% |
| FY2023 | 2023-12-31 | 74.02M | -52.4% |
| FY2022 | 2022-12-31 | 155.38M | +30.4% |
| FY2021 | 2021-12-31 | 119.14M | — |
Cash & Equivalents vs competitors
How SLDB compares with its peers on the latest reported figures
- SLDB's Mar 2026 cash & equivalents of $297.74M is the 4th highest of the 10 companies compared; the peer median is $105.42M.
- Its year-over-year change of +41.4% is the 5th highest of 10, against a peer median of +39.4%.
- Cash & equivalents amounts to 70.4% of total assets for SLDB, versus a peer median of 29.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.05B | +3.2% | +52.1% | 32.3% | |
| Jun 2026 | $676.11M | +39.4% | +73.1% | 68.0% | |
| Mar 2026 | $464.45M | +92.8% | -6.1% | 14.6% | |
| Mar 2026 | $297.74M | +41.4% | -27.2% | 70.4% | |
| Mar 2026 | $124.16M | +75.4% | +8.2% | 47.2% | |
| Mar 2026 | $105.42M | +266.1% | +210.6% | 32.3% | |
| Mar 2026 | $72.49M | -45.7% | +4.8% | 14.1% | |
| Mar 2026 | $71.54M | +7.5% | -17.1% | 29.2% | |
| Sep 2026 | $68.68M | +49.3% | +40.6% | 3.9% | |
| Mar 2026 | $42.15M | -3.4% | -30.7% | 27.0% | |
| Peer median (excluding SLDB) | $105.42M | +39.4% | +8.2% | 29.2% | |
Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 119.14M | 155.38M | 74.02M | 80.24M | 59.9M |
| Short-term Investments | 88.64M | 58.34M | 49.63M | 68.69M | 127.95M |
| Net Receivables | 110K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.71M | 3M | 2.11M | 1.65M | 17.61M |
| Total Current Assets | 222.61M | 219.64M | 129.73M | 157.3M | 205.46M |
| Property, Plant & Equipment (Net) | 7.6M | 38.61M | 33.16M | 29.04M | 26.09M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.16M | 2.01M | 2.04M | 2.32M | 991K |
| Total Non-current Assets | 9.77M | 40.61M | 35.21M | 31.36M | 27.08M |
| Total Assets | 232.38M | 260.25M | 164.94M | 188.66M | 232.54M |
| Account Payables | 4.46M | 3.24M | 2.03M | 4.24M | 3.22M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.1M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 8.08M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.12M | 8.38M | 5.95M | 9.37M | 28.15M |
| Total Current Liabilities | 23.6M | 22.51M | 14.52M | 30.26M | 33.47M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 96K | 0 | 0 | 0 |
| Total Non-current Liabilities | 568K | 26.08M | 23.94M | 21.16M | 19.06M |
| Total Liabilities | 24.17M | 48.59M | 38.46M | 51.42M | 52.53M |
| Common Stock | 7K | 20K | 20K | 40K | 79K |
| Retained Earnings | (476.76M) | (562.74M) | (658.75M) | (783.45M) | (957.78M) |
| Accumulated OCI | (45K) | (68K) | 15K | 47K | 52K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 208.21M | 211.67M | 126.48M | 137.25M | 180.01M |
| Total Debt | 2.06M | 28.55M | 26.27M | 24.18M | 21.16M |
| Net Debt | (117.07M) | (126.84M) | (47.75M) | (56.06M) | (38.74M) |
Solid Biosciences Inc.
NASDAQ:SLDB
Intrinsic Alpha fair value
Locked
Current Price
$6.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.